No actionable trading signal from this filing. Monitor for future financing or clinical catalysts given the cash runway into Q3 2026 per the prior 20-F. The conference panel may generate modest attention but is unlikely to move the stock.
Price Chart
Executive Summary
Innate Pharma announced its Chief Medical Officer will participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference on July 28, 2026. This is a routine conference appearance with no material financial or clinical data disclosed. The filing does not alter the company's fundamental outlook, which remains constrained by the cash runway concerns highlighted in the prior 20-F filing.
Key Facts
- CMO Sonia Quaratino to speak on 'Changing Treatment Landscape in Bladder Cancer' panel at BTIG Virtual Biotechnology Conference on July 28, 2026.
- No new clinical data, financial results, guidance, or business developments were disclosed.
- The filing is a standard conference participation announcement with no material impact on operations or valuation.
Financial Impact
No financial impact; conference participation is routine and non-material.
Risk Factors
- Cash runway limited to Q3 2026 per prior 20-F; financing risk remains the primary concern.
- No new clinical or partnership catalysts announced in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-049273 |
| Document: a260723_6k.htm | 0001628280-26-049273 |
| Document: 0001628280-26-049273-index-headers.html | 0001628280-26-049273 |
| Document: 0001628280-26-049273-index.html | 0001628280-26-049273 |
| Document: 0001628280-26-049273.txt | 0001628280-26-049273 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $1.54 | awaiting T+20 | — | $1.48 (−3.90%) |
Oct 21, 2026 6d ago | 6-K | $1.57 | awaiting T+20 | — | $1.48 (−5.73%) |
Oct 20, 2026 7d ago | 6-K | $1.58 | awaiting T+20 | — | $1.48 (−6.21%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.48 (−22.51%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.48 (−22.51%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.48 (−22.51%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.48 (−22.51%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.48 (−21.28%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.48 (−31.80%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.48 (−32.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers